Rothschild analyst Simon Baker downgrades Moderna stock to Sell from Neutral while doubling his price target.
Yahoo
Skip to navigation
Skip to main content
Skip to right column
Moderna’s Cancer Vaccine Rally Sparks Rare Sell Rating and Projected 44% Stock Drop ·
Barrons.com
·
Graham Hughes/Bloomberg
